Hospital
Catawba Valley Medical Center
Catawba Valley Medical Center was paid $17.37M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoCATAWBA VALLEY MEDICAL CENTER
HICKORY, NC 28602
HICKORY, NC 28602
33aNPI1164495255assigned 02/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.37M
24GClaims370,442
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#34 of 92
Median peer was paid$11.47M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GALLAGHER, PAMELA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,205 | $1.85M | |
| 2019 | 55,072 | $1.83M | |
| 2020 | 33,288 | $1.16M | |
| 2021 | 53,256 | $2.46M | |
| 2022 | 58,652 | $3.66M | |
| 2023 | 57,752 | $3.26M | |
| 2024incomplete | 55,217 | $3.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 20,211 | 17,902 | $5.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 34,560 | 31,557 | $5.14M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 4,182 | 3,798 | $1.17M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.1% | 5,066 | 2,306 | $712K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.6% | 4,201 | 3,728 | $631K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 5,058 | 4,683 | $447K |
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 7,872 | 7,385 | $324K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.9% | 3,224 | 2,681 | $321K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 39,872 | 35,118 | $319K |
| J3490 | Unclassified drugs | 1.8% | 96,322 | 39,257 | $319K |
| 80053 | Comprehensive metabolic panel | 1.5% | 28,656 | 25,564 | $267K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 6,948 | 6,180 | $267K |
104 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 6,310 | $207K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 1,160 | $204K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 155 | $174K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 323 | $171K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,214 | $120K |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,049 | $81K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,916 | $78K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,325 | $74K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,378 | $64K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,379 | $64K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 934 | $61K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 289 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,317 | $50K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 805 | $48K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,546 | $47K |
| 86780 | <1% | 2,923 | $46K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,690 | $44K |
| 80061 | Lipid panel | <1% | 2,482 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 826 | $43K |
| 81001 | <1% | 12,319 | $39K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,886 | $39K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 436 | $29K |
| 76820 | <1% | 276 | $28K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 281 | $28K |
| 84484 | <1% | 2,648 | $21K | |
| 86762 | <1% | 1,211 | $19K | |
| 86787 | <1% | 1,328 | $19K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 99 | $18K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,391 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,821 | $16K |
| 87653 | <1% | 588 | $16K | |
| 86850 | <1% | 1,354 | $15K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 525 | $14K |
| 83690 | <1% | 1,982 | $14K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,683 | $12K |
| 87522 | Neg quan hep c or qual rna | <1% | 367 | $12K |
| 87536 | <1% | 180 | $12K | |
| 87340 | <1% | 1,122 | $11K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,188 | $10K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 42 | $10K |
| 87071 | <1% | 815 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 390 | $8K |
| 83021 | <1% | 444 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 231 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $7K |
| 80320 | <1% | 325 | $7K | |
| 86803 | <1% | 365 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 553 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 136 | $6K |
| 87150 | <1% | 192 | $6K | |
| 82950 | <1% | 1,064 | $5K | |
| 11045 | <1% | 76 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 792 | $5K |
| 81025 | <1% | 533 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 125 | $4K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 70 | $4K |
| 87430 | <1% | 227 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 180 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 64 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 696 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 51 | $2K |
| 82607 | <1% | 81 | $2K | |
| 87486 | <1% | 45 | $2K | |
| 86900 | <1% | 1,252 | $2K | |
| 93798 | <1% | 89 | $2K | |
| 87581 | <1% | 45 | $2K | |
| 86901 | <1% | 1,252 | $2K | |
| 84480 | <1% | 81 | $2K | |
| 86361 | <1% | 38 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 45 | $1K |
| 73630 | <1% | 22 | $1K | |
| 85660 | <1% | 227 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 879 | $1K |
| 84439 | <1% | 76 | $1K | |
| 88142 | <1% | 30 | $889.39 | |
| 83020 | <1% | 48 | $863.53 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 321 | $789.81 |
| 94375 | <1% | 12 | $672.36 | |
| 82728 | <1% | 34 | $624.23 | |
| 94727 | <1% | 12 | $592.74 | |
| 84702 | <1% | 55 | $547.56 | |
| 83655 | <1% | 44 | $542.88 | |
| 83540 | <1% | 44 | $424.01 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 40 | $400.78 |
| 83550 | <1% | 28 | $373.74 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 149 | $356.41 |
| 96367 | <1% | 18 | $354.36 | |
| 94150 | <1% | 12 | $331.61 | |
| 82746 | <1% | 12 | $287.33 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 81 | $214.09 |
| 85610 | <1% | 65 | $202.90 | |
| 80050 | General health panel | <1% | 13 | $141.96 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 43 | $132.37 |
| 81002 | <1% | 722 | $119.04 | |
| 87186 | <1% | 13 | $118.47 | |
| 84436 | <1% | 17 | $113.02 | |
| 87077 | <1% | 13 | $110.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13 | $104.95 |
| 84703 | <1% | 20 | $101.11 | |
| A9270 | Non-covered item or service | <1% | 18 | $19.55 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 47 | $17.16 |
| 99464 | 0% | 23 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 68 | $0.00 |
| 59899 | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGALLAGHER, PAMELA (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Catawba Valley Medical Center | Hickory, NC | $998K |
| Catawba Valley Medical Group, INC | Newton, NC | $892K |
| Catawba Valley Medical Group, Ing | Hickory, NC | $821K |
| Catawba Valley Medical Group, INC | Conover, NC | $599K |
| Catawba Valley Medical Group, INC | Sherrills Ford, NC | $555K |
| Catawba Valley Medical Group INC | Hickory, NC | $509K |
| Catawba Valley Medical Group, INC | Hickory, NC | $481K |
| Catawba Valley Medical Group, INC | Hickory, NC | $477K |
| Catawba Valley Medical Group, INC | Hickory, NC | $423K |
| Catawba Valley Medical Group INC | Taylorsville, NC | $329K |
| Catawba Valley Medical Group INC | Hickory, NC | $277K |
| Catawba Valley Medical Center | Hickory, NC | $247K |
| Catawba Valley Medical Group, INC | Conover, NC | $218K |
| Catawba Valley Medical Group, INC | Taylorsville, NC | $196K |
| Catawba Valley Medical Center | Hickory, NC | $179K |
| Catawba Valley Medical Center | Hickory, NC | $177K |
| Catawba Valley Medical Group, INC | Hickory, NC | $173K |
| Catawba Valley Medical Group, INC | Maiden, NC | $166K |
| Catawba Valley Medical Group, INC | Hickory, NC | $138K |
| Catawba Valley Medical Center | Hickory, NC | $130K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.